GC Biopharma Corp. (KRX:006280)
South Korea flag South Korea · Delayed Price · Currency is KRW
126,400
-1,000 (-0.78%)
Last updated: Mar 28, 2025

GC Biopharma Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2015
Operating Revenue
1,679,8921,626,6441,711,3131,537,8261,504,115
Upgrade
Other Revenue
--0-0-0-
Upgrade
Revenue
1,679,8921,626,6441,711,3131,537,8261,504,115
Upgrade
Revenue Growth (YoY)
3.27%-4.95%11.28%2.24%10.83%
Upgrade
Cost of Revenue
1,199,3481,143,3131,131,3501,018,5851,064,691
Upgrade
Gross Profit
480,544483,331579,962519,240439,425
Upgrade
Selling, General & Admin
265,470258,898292,484282,771242,918
Upgrade
Research & Development
166,198173,487191,347146,030137,987
Upgrade
Other Operating Expenses
1,2771,6242,1651,5941,259
Upgrade
Operating Expenses
448,505449,420499,253445,515389,239
Upgrade
Operating Income
32,03933,91180,71073,72650,186
Upgrade
Interest Expense
-40,439-28,483-18,393-12,501-10,354
Upgrade
Interest & Investment Income
3,6213,4213,7851,6651,555
Upgrade
Earnings From Equity Investments
1,250-40,467--
Upgrade
Currency Exchange Gain (Loss)
7,2451,0102,57013,477-17,517
Upgrade
Other Non Operating Income (Expenses)
-1,4403,147-4,8428,002-913.65
Upgrade
EBT Excluding Unusual Items
2,27613,006104,29684,36822,956
Upgrade
Gain (Loss) on Sale of Investments
-20,799-37,222-18,75981,20031,038
Upgrade
Gain (Loss) on Sale of Assets
-3,761-2,9191906,99158,619
Upgrade
Asset Writedown
-18,088----8,140
Upgrade
Other Unusual Items
-738----
Upgrade
Pretax Income
-41,110-27,13585,728172,559104,474
Upgrade
Income Tax Expense
1,527-7,32616,31335,60915,366
Upgrade
Earnings From Continuing Operations
-42,637-19,80969,415136,95089,108
Upgrade
Earnings From Discontinued Operations
----162.96
Upgrade
Net Income to Company
-42,637-19,80969,415136,95089,271
Upgrade
Minority Interest in Earnings
16,357-6,823-3,962-13,738-8,222
Upgrade
Net Income
-26,280-26,63265,453123,21281,049
Upgrade
Net Income to Common
-26,280-26,63265,453123,21281,049
Upgrade
Net Income Growth
---46.88%52.02%-
Upgrade
Shares Outstanding (Basic)
111111511
Upgrade
Shares Outstanding (Diluted)
111111511
Upgrade
Shares Change (YoY)
-0.03%0.02%125.85%-55.72%-
Upgrade
EPS (Basic)
-2303.00-2333.005734.8724381.797101.34
Upgrade
EPS (Diluted)
-2303.00-2333.005734.8724381.797101.34
Upgrade
EPS Growth
---76.48%243.34%-
Upgrade
Free Cash Flow
-85,452-84,56061,15823,658-46,902
Upgrade
Free Cash Flow Per Share
-7488.36-7407.625358.564681.52-4109.46
Upgrade
Gross Margin
28.61%29.71%33.89%33.77%29.22%
Upgrade
Operating Margin
1.91%2.08%4.72%4.79%3.34%
Upgrade
Profit Margin
-1.56%-1.64%3.82%8.01%5.39%
Upgrade
Free Cash Flow Margin
-5.09%-5.20%3.57%1.54%-3.12%
Upgrade
EBITDA
113,074109,810145,806129,63098,977
Upgrade
EBITDA Margin
6.73%6.75%8.52%8.43%6.58%
Upgrade
D&A For EBITDA
81,03475,89965,09655,90448,791
Upgrade
EBIT
32,03933,91180,71073,72650,186
Upgrade
EBIT Margin
1.91%2.08%4.72%4.79%3.34%
Upgrade
Effective Tax Rate
--19.03%20.64%14.71%
Upgrade
Advertising Expenses
35,23840,73950,72649,01539,770
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.